Skip to content

Advertisement

  • Research article
  • Open Access

Screening for inhibitors of mutacin synthesis in Streptococcus mutans using fluorescent reporter strains

BMC MicrobiologyBMC series – open, inclusive and trusted201818:24

https://doi.org/10.1186/s12866-018-1170-3

  • Received: 16 August 2017
  • Accepted: 20 March 2018
  • Published:

Abstract

Background

Within the polymicrobial dental plaque biofilm, bacteria kill competitors by excreting mixtures of bacteriocins, resulting in improved fitness and survival. Inhibiting their bacteriocin synthesis might therefore be a useful strategy to eliminate specific pathogens. We used Streptococcus mutans, a highly acidogenic inhabitant of dental plaque, as a model and searched for natural products that reduced mutacin synthesis. To this end we fused the promoter of mutacin VI to the GFP+ gene and integrated the construct into the genome of S. mutans UA159 by single homologous recombination.

Results

The resulting reporter strain 423p - gfp + was used to screen 297 secondary metabolites from different sources, mainly myxobacteria and fungi, for their ability to reduce the fluorescence of the fully induced reporter strain by > 50% while growth was almost unaffected (> 90% of control). Seven compounds with different chemical structures and different modes of action were identified. Erinacine C was subsequently validated and shown to inhibit transcription of all three mutacins of S. mutans. The areas of the inhibition zones of the sensor strains S. sanguinis and Lactococcus lactis were reduced by 35% to 61% in comparison to controls in the presence of erinacine C, demonstrating that the amount of active mutacins in the culture supernatants of S. mutans was reduced. Erinacines are cyathane diterpenes that were extracted from cultures of the edible mushroom Hericium erinaceus. They have anti-inflammatory, antimicrobial and neuroprotective effects. For erinacine C, a new biological activity was found here.

Conclusions

We demonstrate the successful development of a whole-cell fluorescent reporter for the screening of natural compounds and report that erinacine C suppresses mutacin synthesis in S. mutans without affecting cell viability.

Keywords

  • Streptococcus
  • Virulence
  • Mutacin
  • Whole-cell screening
  • Fluorescent reporter
  • Myxobacteria
  • Fungi
  • Secondary metabolites

Background

The lack of novel antibiotics in the pipeline of pharmaceutical companies and the simultaneous worldwide increase of antibiotic resistance represent enormous challenges in the re-emerging fight against infectious diseases [1]. In addition, the discovery of the complex functions of the human microbiome in maintaining health and its crucial contribution to the development of the immune system in infants call for completely new strategies [2]. As an alternative to killing the pathogens, quenching their quorum sensing mechanisms has been explored because resistance is expected to be very slow or unlikely. This is because the strategy does not interfere with growth and only changes its phenotype with minimal or no selective pressure [37]. For example, in P. aeruginosa, the cell-cell communication required for establishing virulence was targeted. Mimics of its quorum sensing signal N-(3-oxododecanoyl)-L-homoserine lactone which were structurally similar to the natural AHL but unable to induce quorum sensing were synthesized and competed for the natural AHL resulting in reduced production of the virulence factor pyocyanin [8].

In this context, interest in compounds synthesized by bacteria, fungi, plants and animals has increased [9]. Myxobacteria are a particularly rich source of secondary metabolites [10] and have recently been found to yield various novel chemical entities that appear promising as starting points for development of novel antibiotics [1113]. Natural compounds have unique, highly complex chemical structures and dedicated biosynthetic pathways and have been optimized in evolution for improving the survival of the producing organism; their biological function is therefore context dependent and often not known [14]. In particular from fungi, numerous novel unique metabolites are continuously being discovered, which may serve as basis for novel lead structures to combat bacterial pathogens [15]. For example, caspofungin, a semi-synthetic derivative of pneumocadin from Glarea lozoyensis, was active against Candida albicans biofilms and was the first fungal inhibitor that has been approved for treatment against invasive candidiasis [16]. Aspergillomarasmine A (AMA), from Aspergillus versicolor was recently identified to inhibit the function of metallo-β- lactamase NDM-1 of Enterobacteriaceae. It sequestered the Zn2+ required activity of NDM-1 metalloproteinase, which opens the β-lactam ring of the antibiotic thereby causing resistance. However, AMA with its sequestration ability re-sensitizes bacteria to meropenem [17].

Here we focused on Streptococcus mutans, an important component of dental plaque. S. mutans was considered the etiological agent of caries based on cultivation-dependent analyses [18]. Current next generation sequencing approaches found S. mutans to be a minor component of caries lesions and revealed the contribution of many more oral species to caries development [1922]. In fact Veillonella sp. was identified to be predictive of early childhood caries, but not S. mutans [23]. Here we use S. mutans as a model and test a general strategy that might be transferable to other streptococci. For this aim, S. mutans is ideally suited because it is very well studied and many genetic tools are available.

Here we now targeted the ability to produce mutacins, the peptide antibiotics synthesized by S. mutans [24]. According to their structure, they are divided into non-lantibiotics and lantibiotics, of which the lantibiotic mutacin 1140 has attracted large interest as anti-bacterial drug [25, 26]. Previously a strain of S. mutans was developed that produced elevated levels of mutacin 1140 while being impaired in acid production [27, 28]. It was planned to be applied as a probiotic to outcompete wild-type S. mutans for the so-called replacement therapy of dental caries and underwent phase 1 clinical testing [29].

Here we pursued an alternative approach. Since mutacins kill competitors [30, 31], suppression of their synthesis should impair the fitness of S. mutans in the polymicrobial dental plaque biofilm. Natural compounds that suppress mutacin production might be more easily approved by the authorities than a genetically engineered probiotic. Therefore we developed whole-cell reporters of S. mutans UA159 where we fused the promoters of mutacin synthesis genes to the enhanced GFP+ and monitored fluorescence as a proxy of gene expression. Mutacin synthesis in S. mutans is under the control of the autoinducer MIP (mutacin inducing peptide) [32]. Thus we induced mutacin synthesis by MIP and monitored reduction of fluorescence in the presence of test compounds. In such a way we screened 297 natural compounds from myxobacteria and fungi, of which the most interesting compound was subsequently validated.

Methods

Bacterial strains and cultivation conditions

Escherichia coli DH5α was grown aerobically in Luriani Bertani (LB) broth (Carl Roth, X969.2) at 37 °C. Selection of positive clones in E. coli was done on LB plates with 1.5% agar and 300 μg/ml erythromycin (Sigma Aldrich, E5389). Overnight cultures of Streptococcus mutans UA159 (ATCC 700610) were routinely grown in Todd Hewitt broth supplemented with 0.5% (w/v) yeast extract (THBY; Becton Dickinson, 249,240, 212,750) at 37 °C and 5% CO2 without shaking. 10 μg/ml of erythromycin was used for selection of positive clones on THBY agar. The indicator strains L. lactis for SMU_1914 and S. sanguinis for SMU_150 were routinely grown in THBY broth at 37 °C and were overlaid with 0.7% THBY soft agar in the mutacin overlay assay. For screening, the mutacin expression reporters were grown on a semi-defined BM medium [33] where the concentration of glucose was increased to 0.5%. BM medium was chosen because it had minimal background fluorescence.

Construction of fluorescent reporter strains

Plasmid pAE03 [34] was used for the construction of the mutacin expression reporters. The plasmid encodes an erythromycin cassette for selection and a promotorless-GFP+ fluorophore to which the respective mutacin promotors were fused. The promotors of the mutacin genes SMU.423 (mutacin VI), SMU.150 (mutacin IV) and SMU.1914 (mutacin V) were amplified using fusion polymerase (New England Biolabs, M0530S) and the primers listed (see Additional file 1). PCR products were cloned into the plasmid pAE03 using the Clone EZ Genscript kit (L00339). The recombination reaction was carried out in a thermocycler at 22 °C for 30 min. The mixture was transformed into E.coli DH5α competent cells and clones were selected on THBY agar with 300 μg/ml erythromycin (Sigma Aldrich, E5389). From the positive clones, plasmids were purified, transformed into S. mutans UA159 and selected on THBY agar with 10 μg/ml of erythromycin. Positive clones where promoter and GFP+ were fused by single homologous recombination were confirmed by PCR and sequencing.

Construction of deletion mutants in S. mutans

The mutacin genes were amplified from genomic DNA of S. mutans with specific primers (see Additional file 1). 5′ end of the forward and reverse primer for erythromycin, and P2/P3 sequences of the gene amplification primers were incorporated with restriction sites (AscI and FseI) to create overhangs for ligation. The amplified sequences were digested with the restriction enzymes AseI and FseI (New England biolabs, R0558S, R0588S). The digested fragments were purified using QIAquick PCR purification kit (28106). The concentration of the fragments was determined using nanodrop and confirmed by agarose gel electrophoresis. The digested erythromycin cassette and the flanking regions were ligated with T4 DNA ligase (New England biolabs, M0202). The ligation reaction was carried out at RT for 10 min followed by inactivation at 65 °C for 10 min in a thermocycler. The ligation product was transformed into S. mutans UA159 and positive clones were selected by 10 μg/ml of erythromycin. Deletion constructs were verified by PCR and sequencing.

Transformation in E. coli and S. mutans

Transformation in E. coli: SOC medium was thawed at 37 °C and TSS solution was placed on ice. An overnight culture of E. coli DH5α was diluted 1:100 in 5 ml sterile LB broth and incubated at 37 °C at 200 rpm until an OD 0.3–0.4. 1 ml of the culture was centrifuged (13,000 rpm, 1 min), the supernatant was discarded and the pellet re-suspended in 100 μl ice-cold TSS solution. The plasmid construct (5–10 μl) was added to the cells and incubated on ice for 30 min followed by a heat shock at 42 °C for 45 min with subsequent transfer to ice for 2 min. The transformation mixture was transferred to 600 μl SOC medium and incubated for 1 h in the 37 °C shaker. The cells were centrifuged (10,000 rpm, 2 min) and 550 μl of the SOC medium was removed. The pellet was re-suspended in the residual medium and plated on LB agar with antibiotics when needed. The plates were incubated at 37 °C overnight. Positive colonies were picked, cultivated in LB, DNA was isolated and the construct was verified by sequencing.

Transformation in S. mutans: An overnight culture of S. mutans was diluted 1:10 in 5 ml THBY medium. The cells were incubated at 37 °C and 5% CO2 for 2 h. 5 μl of 1 mM MIP was added and further incubated at 37 °C for 30 min. 200 μl of the culture was placed in an Eppendorf tube, DNA was added and the cells were incubated for 3 h. Selection of constructs was performed on THBY agar with the respective antibiotics. Positive clones were picked, cultivated in THBY, DNA was isolated and the constructs were verified by sequencing.

Screen for suppression of mutacin expression

The mutacin reporter strains (150p, 1914p and 423p with gfp+) were cultivated in THBY broth with 10 μg/ml erythromycin overnight. 15 ml of the cultures were harvested by centrifugation (Thermo scientific X1R, 6000 rpm, 15 min, 4 °C). The supernatant was decanted and pellets were gently re-suspended in 7 ml of freshly prepared BM-glucose medium using a pipette. The OD600 of the cultures was adjusted to 0.2 using the Ultrospec 3100 pro UV/VIS spectrophotometer.

The assay was performed with a final culture volume of 200 μl per well on a 96 well optical bottom polystyrene black microtitre plate (Thermo Scientific, 165305). 0.5 μl of 1 mM mutacin inducing peptide (MIP) synthesized in-house and 10 μl of the test compounds solved in methanol or DMSO were added to each well. Wells with MIP but without test compound served as controls. Plates were incubated at 37 °C, 5% CO2, without shaking, for 4 to 24 h. Absorbance (P620/8 nm filter) and fluorescence (485nmexcitation/535 nm emission) were determined with a plate reader (Perkin Elmer, Victor31420 Multilabel Counter). For the KOM and MWIS libraries, the assay was performed in triplicate, the SAAR plates contained each compound once. Data are mean and standard deviation from two independent experiments for the KOM and MWIS libraries. Validation experiments were performed in triplicate assays and two biological replicates.

Natural product libraries

A total of 297 compounds were screened and were derived from three different natural product libraries which are named after the groups that provided them KOM (Microbial Communication, HZI, Germany), MWIS (Microbial Drugs, HZI, Germany) and SAAR (Helmholtz-Institute of Pharmaceutical Research, Saarbrücken, Germany).

In case of KOM and MWIS, the stocks of the compounds were provided in methanol. These libraries were screened at a final concentration of 5 μg and 0.5 μg per ml in triplicates. Compounds from SAAR were provided on a polypropylene micro-titre plate with 5 μl of the compound at 1 mM concentration in DMSO. Plates were stored at − 80 °C. Shortly before screening, the plate was retrieved from − 80 °C and thawed at room temperature. To pool the compounds to the bottom, the plate was centrifuged in a microplate centrifuge (Thermo scientific Heraeus labofuge 400 R) at 1500 rpm for 5 min and the compounds were transferred to an optical bottom polystyrene black microtitre plate for testing. The final concentration of the compounds from the SAAR library was 25 μM.

Mutacin overlay assay

Overnight cultures in THBY of S. mutans UA159 and the deletion mutants Δ150, Δ1914 and Δ423 were adjusted to OD600 of 0.2. To each culture erinacine C (5 μg/ml) was added, incubated (45 min) and then centrifuged (7500 rpm, 5 min). The supernatant was discarded and the pellet was re-suspended in 50 μl fresh THBY. 2.5 μl of each sample was spotted on THBY agar. The plates were incubated for 4–6 h. Afterwards, 2.5 μl of 1 mM MIP and 2.5 μl of 0.2 mg/ml erinacine C was added to the spot and incubated overnight. On the following day, overnight cultures of L. lactis and S. sanguinis were adjusted to an OD600 of 0.1 and cultivated for 2.5 h. After 2.5 h, 100 μl of the mid-log phase cultures was diluted in 6 ml of 0.7% THBY top agar and overlaid. After 20 h incubation, the area of inhibition around each spot was measured.

Results

The mutacin VI reporter shows strong population wide expression upon induction by MIP

S. mutans produces the three non-lantibiotic mutacins IV, V and VI. Mutacin IV, which is also termed NlmAB, acts against many streptococcal strains, while mutacin V (also termed NlmC or CipB) is active against non-streptococcal species [35]. The activity of mutacin VI was only detected in a strain overexpressing the novel regulatory system BrsRM [36, 37] and thus no natural indicator strain is known. In spite of this lack of knowledge, we initially used the mutacin VI (SMU.423) reporter for screening because natural compounds might have elicited strong responses and this would have been an important novel finding. The fully induced reporter construct showed the same growth as the wild-type (see Additional file 2) indicating that the expression of GFP+ did not represent a metabolic burden and should not affect screening results. As expected, transcription of mutacin VI occurred in a population wide manner in THBY upon induction by MIP (Fig. 1). Transcription of all mutacin genes is controlled by the response regulator ComE which is activated directly through the ComDE two-component system [32]. Deletion of the mutacin VI open reading frame had no influence on growth (see Additional file 3).
Fig. 1
Fig. 1

Population wide activation of the mutacin VI promoter of S. mutans UA159 by MIP. Reporter strain S. mutans 423p – gfp + was cultivated in BM medium supplemented with 0.5% glucose and 2.5 μM MIP (for induction of mutacin transcription). After 8 h of growth (37 °C, 5% CO2) cells were observed under the fluorescence microscope. See Methods for further details

Prescreening for inhibitors of mutacin VI transcription

Altogether 297 natural compounds were used for pre-screening the mutacin VI reporter strain. They contained fungal and myxobacterial secondary metabolites and were available as DMSO or methanol stocks, large fraction of which were provided in microtiter format at 25 μM [38]. Compounds were scored positive if they reduced the transcription of the maximally induced mutacin VI gene by more than 50% at three time-points without a strong effect on growth (OD600 > 90% of control induced by MIP but not treated by natural compound). Three time points were measured (t1, t2 and t3 in Table 1), namely at 4 or 6 h, 8 h and 24 h. The time points were chosen because mutacin production remains high during the onset of stationary phase or when the cell density reaches maximum. They represented exponential growth (between 4 and 6 h), onset of stationary phase (8 h) and stationary growth phase (> 8 h up to 24 h). Of the 297 compounds, 49 inhibited growth, and 18 showed strong background fluorescence. From the remaining 230 compounds, 7 were scored positive (Table 1). The strongest inhibitor was myxovirescin D which reduced reporter fluorescence to 13% of the control. Interestingly, variants of ambruticin, an anti-fungal compound [39] were able to increase the expression of the fully induced mutacin VI promoter even further (> 25%).
Table 1

Prescreening results for suppressors of mutacin VI transcription

Compound

% fluorescence

Structure

References

t1

t2

t3

Erinacine C

43

38

40

[47]

Noricumazol A

33

29

24

[42, 54, 55]

Myxovirescin D

26

18

13

[43]

Chondrochloren B

47

38

25

[56, 57]

Aurachin A

40

26

16

[44, 58, 59]

Myxopyronin A

23

20

27

[45, 6062]

Jerangolid E

42

42

35

[46, 63]

Compounds that reduced fluorescence of the mutacin VI reporter at three time points (t1, t2, t3) by more than 50% without affecting growth (less than 10% reduction in OD600) are shown here. The total number of tested compounds was 297

Erinacine C inhibits transcription of all three mutacins of S. mutans UA159

From the seven compounds shown in Table 1 we chose erinacine C for further investigations. First, we tested if the results of the prescreening could be confirmed in laboratory culture. Then, we tested if this compound also suppressed the transcription of the two other mutacins of S. mutans. Mutacin IV is transcribed weakly and kills closely related Streptococci [35], while mutacin V is transcribed at much higher rates [32] and kills additionally Lactococcus species. To this end we used reporter strains 1914p – gfp + (for the promoter of SMU.1914, mutacin V) and reporter strain 150p – gfp + (for the promoter of SMU.150, mutacin IV). Figure 2 shows that at 5 μg/ml final concentration, erinacine C also reduced expression of mutacin IV and V, although the strength of inhibition varied. There was no growth inhibition at this concentration. Lower concentrations of erinacine C were inactive (Fig. 2, Additional file 4). At higher concentrations of erinacine C, growth was increasingly impaired (Additional file 4). At 20 μg/ml erinacine C, growth of the S. mutans reporter strains was reduced to approximately 50% of the controls.
Fig. 2
Fig. 2

Reduction of mutacin IV, V and VI expression by erinacine C. Upper panel a: Chemical structure of erinacine C [47]. Lower panel b: Reporter strains 150p, 1914p and 423p (tagged with gfp+) were cultivated as in Fig. 1, except that erinacine C was added at the same time as MIP at 0.5 μg/ml or 5 μg/ml (final concentration). Data show mean and standard deviation of two biological replicates which were conducted with triplicate subsamples

Erinacine C protects indicator strains from killing by S. mutans

Post-transcriptional regulatory mechanisms have a large influence on the expression of proteins and peptides, and play a particularly important role for the synthesis and maturation especially of bacteriocins. For example, in S. mutans transcription of mutacin V is induced in minimal medium, yet the active bacteriocin was not detectable [32]. Therefore we investigated if erinacine C could reduce the amount of mutacins produced by S. mutans. We first determined the sensitivity of the sensor strains Lactococcus lactis and S. sanguinis against the three mutacins of S. mutans. To this end we constructed gene deletion mutants for each of the three mutacins and tested how growth of the sensor strains L. lactis and S. sanguinis was influenced by these mutants. Additional file 5 shows that L. lactis was killed mainly by mutacin V and S. sanguinis mainly by mutacin IV, as expected. Deletion of SMU.423 had no influence on the zone of inhibition of both strains, confirming that mutacin VI is either not produced, or is not active against these two sensor strains.

Finally we incubated the wild-type S. mutans UA159 with erinacine C. Figure 3 shows an example for the area of inhibition, and Table 2 shows the data from all experiments. The area of inhibition for S. sanguinis was reduced from 162 ± 24 mm2 to 106 ± 9 mm2 in the presence of erinacine C, representing 35% reduction. The effect on L. lactis, indicator for the highly expressed mutacin V, was even stronger (42% reduction of the area of inhibition). In the presence of MIP, the inhibition areas increased for both sensor strains as expected. Interestingly, addition of MIP increased the effect of erinacine C: If both erinacine C and MIP were applied, the area of inhibition was reduced by 47% for S. sanguinis and by 61% for L. lactis. The data show that erinacine C not only inhibited the transcription of mutacins, but the amount of the mature, active mutacin antibiotics in the cultivation medium was reduced in comparison to the untreated S. mutans UA159 culture. As a result, killing of the sensor strains was reduced. We hypothesize that erinacine C might similarly inhibit the synthesis of mutacins in dental plaque. S. mutans would therefore be less dangerous to competing bacteria and have a reduced fitness. The findings of our study support future studies aimed at evaluating the loss of virulence in a plaque/biofilm study.
Fig. 3
Fig. 3

Erinacine C protects indicator strains Lactococcus lactis and S. sanguinis from killing by S. mutans. Overnight cultures of S. mutans UA159 in THBY (with and without MIP or erinacine C) were spotted on THBY plates and incubated for 4–6 h. Then, the plates were overlaid with exponential phase cultures of indicator strains grown in THBY and suspended in soft agar (0.7%). After 20 h of incubation (37 °C, 5% CO2) the area of zone of inhibition was measured. The image is a compilation of single technical replicate (cropped from the incubated agar plates) for the indicator strains and compound treatment after 20 h incubation

Table 2

Reduced killing of mutacin IV and V indicator strains in the presence of erinacine C

 

Treatment

Indicator strain

control

+ Erinacine C

+ MIP

+ Erinacine C + MIP

Streptococcus sanguinis

162 ± 24

106 ± 9

239 ± 31

128 ± 12

Lactococcus lactis

121 ± 13

71 ± 8

168 ± 24

66 ± 6

Erinacine C was provided to S. mutans at 5 μg/ml final concentration, and MIP at 2.5 μg/ml final concentration. S. sanguinis is a specific indicator stain for mutacin IV, and Lactococcus lactis for mutacin V. See Methods for details on overlay assay. The area of the zone of inhibition was calculated and the data are mean and standard deviation of three biological replicates

Discussion

Pharmaceutical industry has in the past routinely been using screens based on purified enzymes in high-throughput, triggered by comparative genomics which allowed identifying potential drug targets [40]. Although these screens can be automatized and used for testing huge synthetic libraries, the number of hits that were able to act on whole cells was disappointingly small (e.g. [41]). Using whole-cell screens has the advantage of finding only those molecules that are active against live cells. The disadvantage is that such screens are not easily automated and miniaturized, results depend on the physiological state of the cells, and most importantly, the mode of action of the compound and its molecular target remain unknown.

The seven compounds discovered here to inhibit mutacin transcription belong to completely different chemical classes of secondary metabolites (Table 1), thus they most probably reduce transcription of mutacins by different mechanisms. They also have entirely different modes of action: Noricumazol is a cation channel blocker [42], myxovirescin interferes with cell-wall synthesis [43], aurachin blocks the respiratory chain [44], and myxopyronin is an inhibitor of RNA polymerase [45]. The modes of action are unknown for chondrochloren and jerangolid, although the latter has been reported to change membrane permeability of the yeast Hansenula anomala [46]. The activity of the compounds on the mutacin reporter strains therefore most likely represents a secondary effect and the exact mechanism would have to be determined.

Erinacines are cyathane diterpenes produced by mycelial cultures of the edible and medicinal mushroom Hericium erinaceus and were originally reported to stimulate nerve growth factor biosynthesis [47]. The fruiting bodies as well as the mycelia of this species have been studied intensively in the past decades, and the most important findings were recently compiled in a review [48]. The compounds tested in the current study were derived from a project that recently resulted in the discovery of the novel corallocins from the related species, Hericium coralloides [49]. However, these neurotropic metabolites, as well as several other metabolites obtained from cultures and basidiomata of Hericium species, were found devoid of activities in the present study. Erinacine C is presently being prepared in large quantities by fermentation to further elucidate its biochemical mode of action and to further characterise its antiinfective and neurotropic activity.

In this study, erinacine C was demonstrated to suppress mutacin synthesis in S. mutans which defines a new biological activity for this molecule. No other study on the activity of erinacine C on bacteria was found, except one which reported a weak inhibition of S. mutans by extracts from H. erinaceus in a disc diffusion assay [50]. To show that reduction of mutacin biosynthesis by erinacine C reduces the fitness of S. mutans in vivo, it would be necessary to study the effect of this compound on the survival of S. mutans in multi-species oral biofilm models [51] or dental plaque communities.

Interestingly, erinacine C reduced the transcription of all three mutacins of S. mutans, and synthesis and maturation of at least two of them. Therefore the target of erinacine C must be upstream of the individual synthesis genes and common for all three mutacins. The mutacin synthesis in S. mutans is regulated by the two-component system ComDE and the quorum sensing signal MIP (mutacin inducing peptide) [32]. The signaling molecule MIP is secreted into the environment, and after reaching a certain concentration binds to the transmembrane histidine kinase ComD. This leads to the phosphorylation of its cognate cytoplasmic response regulator ComE. Transcription of all three mutacins is initiated by binding of phosphorylated ComE to specific promoter regions in the bacteriocin genes. Since transcription of all three mutacins was supressed by erinacine C, we hypothesize that this compound interacted with the ComDE signalling cascade. It would be interesting to investigate this hypothesis to see if erinacine C interferes with ComDE of S. mutans, and if it possibly interferes with two-component systems of other bacteria, which would make it an interesting anti-virulence molecule. Previously walkmycin, a complex secondary metabolite from Streptomyces sp., was shown to inhibit autophosphorylation of histidine kinases of S. mutans UA159 and thus reduce its virulence [52, 53].

Conclusion

In this study, we demonstrated that a reporter strain for a gene that is important in terms of the ecology of the organism can be a useful screening tool. The observed reduction of mutacin synthesis might impair the survival of S. mutans in dental plaque and thus its virulence, but further studies are needed to show this. The strategy could be applied to other pathogens and other genes of interest.

Abbreviations

AHL: 

acylated homoserine lactone

AMA: 

Aspergillomarasmine A.

BM: 

Biofilm medium

DMSO: 

Dimethyl-sulfoxide

DNA: 

Ddesoxyribonucleic acid

GFP: 

Green fluorescent protein

HZI: 

Helmholtz-Center for Infection Research

KOM: 

Natural compound library from the research group “Microbial Communication” (KOM) at the Helmholtz-Center for Infection Research

LB: 

Luria Bertani

MIP: 

Mutacin inducing peptide

MWIS : 

Natural compound library from the department Microbial Drugs (MWIS), Helmholtz-Center for Infection Research, Germany

NDM-1: 

Metalloproteinase

OD: 

Optical density

PCR: 

Polymerase chain reaction

rpm: 

Rounds per minute

RT: 

Room temperature

SAAR: 

Natural compound library from the Helmholtz-Institute of Pharmaceutical Research, Saarbrücken, Germany

SOC: 

Medium used in the last step of transformation

THBY: 

Todd Hewitt broth supplemented with 0.5% (w/v) yeast extract

TSS: 

Buffer to make chemically competent cells

VICTOR: 

Multilabel fluorescent plate reader

Declarations

Acknowledgements

We thank Bettina Elxnat for excellent technical assistance. We are grateful to Dr. Jennifer Herrmann, Dr. Rolf Jansen, Ms. Kerstin Schober and Ms. Viktoria Schmitt for supplying the library compounds.

Funding

This work was funded by a grant for PP from the MINAS Graduate School and by the German Ministry for Research and Technology (BMBF) in the program e:bio (grant number 031299A). The funders had no role in the design of the study, collection, analysis and interpretation of data and writing the manuscript.

Availability of data and materials

The datasets analysed during the current study are available from the corresponding author upon reasonable request.

Authors’ contributions

PP conducted the experiments and wrote the draft of the paper; MR provided strains and supervised laboratory work; KW provided compounds for testing; IWD designed the study; MS and IWD finalized the manuscript. All authors analysed and interpreted the data, were involved in drafting the manuscript and revising it critically, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Helmholtz-Center for Infection Research, Group Microbial Communication, Inhoffenstr. 7, 38124 Braunschweig, Germany
(2)
Helmholtz-Center for Infection Research, Department of Microbial Drugs, Inhoffenstr. 7, 38124 Braunschweig, Germany

References

  1. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev. 2011;24:71–109.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Heras B, Scanlon MJ, Martin JL. Targeting virulence not viability in the search for future antibacterials. Br J Clin Pharmacol. 2015;79:208–15.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Gill EE, Franco OL, Hancock RE. Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens. Chem Biol Drug Des. 2015;85:56–78.View ArticlePubMedGoogle Scholar
  4. Hentzer M, Riedel K, Rasmussen TB, Heydorn A, Andersen JB, Parsek MR, Rice SA, Eberl L, Molin S, Hoiby N, Kjelleberg S, Givskov M. Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology (Reading, England). 2002;148:87–102.View ArticleGoogle Scholar
  5. Hentzer M, Wu H, Andersen JB, Riedel K, Rasmussen TB, Bagge N, Kumar N, Schembri MA, Song Z, Kristoffersen P, Manefield M, Costerton JW, Molin S, Eberl L, Steinberg P, Kjelleberg S, Hoiby N, Givskov M. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J. 2003;22:3803–15.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Rasko DA, Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov. 2010;9:117–28.View ArticlePubMedGoogle Scholar
  7. Sully EK, Malachowa N, Elmore BO, Alexander SM, Femling JK, Gray BM, DeLeo FR, Otto M, Cheung AL, Edwards BS, Sklar LA, Horswill AR, Hall PR, Gresham HD. Selective chemical inhibition of agr quorum sensing in Staphylococcus aureus promotes host defense with minimal impact on resistance. PLoS Pathog. 2014;10:e1004174.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Morkunas B, Galloway WR, Wright M, Ibbeson BM, Hodgkinson JT, O'Connell KM, Bartolucci N, Della VM, Welch M, Spring DR. Inhibition of the production of the Pseudomonas aeruginosa virulence factor pyocyanin in wild-type cells by quorum sensing autoinducer-mimics. Org Biomol Chem. 2012;10:8452–64.View ArticlePubMedGoogle Scholar
  9. Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015;14:111–29.View ArticlePubMedGoogle Scholar
  10. Herrmann J, Fayad AA, Muller R. Natural products from myxobacteria: novel metabolites and bioactivities. Nat Prod Rep. 2017;34:135–60.View ArticlePubMedGoogle Scholar
  11. Baumann S, Herrmann J, Raju R, Steinmetz H, Mohr KI, Huttel S, Harmrolfs K, Stadler M, Muller R. Cystobactamids: myxobacterial topoisomerase inhibitors exhibiting potent antibacterial activity. Angew Chem Int Ed Engl. 2014;53:14605–9.View ArticlePubMedGoogle Scholar
  12. Surup F, Viehrig K, Mohr KI, Herrmann J, Jansen R, Muller R. Disciformycins a and B: 12-membered macrolide glycoside antibiotics from the myxobacterium Pyxidicoccus fallax active against multiresistant staphylococci. Angew Chem Int Ed Engl. 2014;53:13588–91.View ArticlePubMedGoogle Scholar
  13. Schieferdecker S, Konig S, Weigel C, Dahse HM, Werz O, Nett M. Structure and biosynthetic assembly of gulmirecins, macrolide antibiotics from the predatory bacterium Pyxidicoccus fallax. Chemistry. 2014;20:15933–40.View ArticlePubMedGoogle Scholar
  14. Ji HF, Li XJ, Zhang HY. Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO Rep. 2009;10:194–200.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Karwehl S, Stadler M. Exploitation of fungal biodiversity for discovery of novel antibiotics. Curr Top Microbiol Immunol. 2016;398:303–38.PubMedGoogle Scholar
  16. Bachmann SP, VandeWalle K, Ramage G, Patterson TF, Wickes BL, Graybill JR, Lopez-Ribot JL. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother. 2002;46:3591–6.View ArticlePubMedPubMed CentralGoogle Scholar
  17. King AM, Reid-Yu SA, Wang W, King DT, De PG, Strynadka NC, Walsh TR, Coombes BK, Wright GD. Aspergillomarasmine A overcomes metallo-beta-lactamase antibiotic resistance. Nature. 2014;510:503–6.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Hamada S, Slade HD. Biology, immunology, and cariogenicity of Streptococcus mutans. Microbiol Rev. 1980;44:331–84.PubMedPubMed CentralGoogle Scholar
  19. Simon-Soro A, Guillen-Navarro M, Mira A. Metatranscriptomics reveals overall active bacterial composition in caries lesions. J Oral Microbiol. 2014;6:25443.View ArticlePubMedGoogle Scholar
  20. Simon-Soro A, Mira A. Solving the etiology of dental caries. Trends Microbiol. 2015;23:76–82.View ArticlePubMedGoogle Scholar
  21. Simon-Soro A, Belda-Ferre P, Cabrera-Rubio R, Alcaraz LD, Mira A. A tissue-dependent hypothesis of dental caries. Caries Res. 2013;47:591–600.View ArticlePubMedGoogle Scholar
  22. Benitez-Paez A, Belda-Ferre P, Simon-Soro A, Mira A. Microbiota diversity and gene expression dynamics in human oral biofilms. BMC Genomics. 2014;15:311.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Teng F, Yang F, Huang S, Bo C, Xu ZZ, Amir A, Knight R, Ling J, Xu J. Prediction of early childhood caries via spatial-temporal variations of oral microbiota. Cell Host Microbe. 2015;18:296–306.View ArticlePubMedGoogle Scholar
  24. Merritt J, Qi F. The mutacins of Streptococcus mutans: regulation and ecology. Mol Oral Microbiol. 2012;27:57–69.View ArticlePubMedGoogle Scholar
  25. Chen S, Wilson-Stanford S, Cromwell W, Hillman JD, Guerrero A, Allen CA, Sorg JA, Smith L. Site-directed mutations in the lanthipeptide mutacin 1140. Appl Environ Microbiol. 2013;79:4015–23.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Ongey EL, Yassi H, Pflugmacher S, Neubauer P. Pharmacological and pharmacokinetic properties of lanthipeptides undergoing clinical studies. Biotechnol Lett. 2017;39:473–82.View ArticlePubMedGoogle Scholar
  27. Hillman JD, Brooks TA, Michalek SM, Harmon CC, Snoep JL, van Der Weijden CC. Construction and characterization of an effector strain of Streptococcus mutans for replacement therapy of dental caries. Infect Immun. 2000;68:543–9.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Hillman JD. Genetically modified Streptococcus mutans for the prevention of dental caries. Antonie Van Leeuwenhoek. 2002;82:361–6.View ArticlePubMedGoogle Scholar
  29. Hillman JD, Mo J, McDonell E, Cvitkovitch D, Hillman CH. Modification of an effector strain for replacement therapy of dental caries to enable clinical safety trials. J Appl Microbiol. 2007;102:1209–19.View ArticlePubMedGoogle Scholar
  30. Kreth J, Merritt J, Shi W, Qi F. Competition and coexistence between Streptococcus mutans and Streptococcus sanguinis in the dental biofilm. J Bacteriol. 2005;187:7193–203.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Kreth J, Zhang Y, Herzberg MC. Streptococcal antagonism in oral biofilms: Streptococcus sanguinis and Streptococcus gordonii interference with Streptococcus mutans. J Bacteriol. 2008;190:4632–40.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Reck M, Tomasch J, Wagner-Dobler I. The alternative sigma factor SigX controls Bacteriocin synthesis and competence, the two quorum sensing regulated traits in Streptococcus mutans. PLoS Genet. 2015;11:e1005353.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Loo CY, Corliss DA, Ganeshkumar N. Streptococcus gordonii biofilm formation: identification of genes that code for biofilm phenotypes. J Bacteriol. 2000;182:1374–82.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Eberhardt A, Wu LJ, Errington J, Vollmer W, Veening JW. Cellular localization of choline-utilization proteins in Streptococcus pneumoniae using novel fluorescent reporter systems. Mol Microbiol. 2009;74:395–408.View ArticlePubMedGoogle Scholar
  35. Hossain MS, Biswas I. Mutacins from Streptococcus mutans UA159 are active against multiple streptococcal species. Appl Environ Microbiol. 2011;77:2428–34.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Okinaga T, Niu G, Xie Z, Qi F, Merritt J. The hdrRM operon of Streptococcus mutans encodes a novel regulatory system for coordinated competence development and bacteriocin production. J Bacteriol. 2010;192:1844–52.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Xie Z, Okinaga T, Niu G, Qi F, Merritt J. Identification of a novel bacteriocin regulatory system in Streptococcus mutans. Mol Microbiol. 2010;78:1431–47.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Maurer CK, Fruth M, Empting M, Avrutina O, Hossmann J, Nadmid S, Gorges J, Herrmann J, Kazmaier U, Dersch P, Muller R, Hartmann RW. Discovery of the first small-molecule CsrA-RNA interaction inhibitors using biophysical screening technologies. Future Med Chem. 2016;8:931–47.View ArticlePubMedGoogle Scholar
  39. Knauth P, Reichenbach H. On the mechanism of action of the myxobacterial fungicide ambruticin. J Antibiot (Tokyo). 2000;53:1182–90.View ArticleGoogle Scholar
  40. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007;6:29–40.View ArticlePubMedGoogle Scholar
  41. Eadsforth TC, Gardiner M, Maluf FV, McElroy S, James D, Frearson J, Gray D, Hunter WN. Assessment of Pseudomonas aeruginosa N5,N10-methylenetetrahydrofolate dehydrogenase-cyclohydrolase as a potential antibacterial drug target. PLoS One. 2012;7:e35973.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Barbier J, Jansen R, Irschik H, Benson S, Gerth K, Bohlendorf B, Hofle G, Reichenbach H, Wegner J, Zeilinger C, Kirschning A, Muller R. Isolation and total synthesis of icumazoles and noricumazoles--antifungal antibiotics and cation-channel blockers from Sorangium cellulosum. Angew Chem Int Ed Engl. 2012;51:1256–60.View ArticlePubMedGoogle Scholar
  43. Gerth K, Irschik H, Reichenbach H, Trowitzsch W. The myxovirescins, a family of antibiotics from Myxococcus virescens (Myxobacterales). J Antibiot (Tokyo). 1982;35:1454–9.View ArticleGoogle Scholar
  44. Kunze B, Hofle G, Reichenbach H. The aurachins, new quinoline antibiotics from myxobacteria: production, physico-chemical and biological properties. J Antibiot (Tokyo). 1987;40:258–65.View ArticleGoogle Scholar
  45. Belogurov GA, Vassylyeva MN, Sevostyanova A, Appleman JR, Xiang AX, Lira R, Webber SE, Klyuyev S, Nudler E, Artsimovitch I, Vassylyev DG. Transcription inactivation through local refolding of the RNA polymerase structure. Nature. 2009;457:332–5.View ArticlePubMedGoogle Scholar
  46. Gerth K, Washausen P, Hofle G, Irschik H, Reichenbach H. The jerangolids: a family of new antifungal compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties of jerangolid a. J Antibiot (Tokyo). 1996;49:71–5.View ArticleGoogle Scholar
  47. Kawagishi H, Shimada A, Shirai R, Okamoto K, Ojima F, Sakamoto H, Ishiguro Y, Furukawa S. Erinacines A, B and C, strong stimulators of nerve growth factor (NGF) synthesis, from the mycelia of Hericium erinaceum. Tetrahedron Lett. 1994;35:1569–72.View ArticleGoogle Scholar
  48. Thongbai B, Rapior S, Wittstein K, Hyde KD, Stadler M. Hericium erinaceus, an amazing medicinal mushroom. Mycol Progr. 2015;14:1–23.View ArticleGoogle Scholar
  49. Wittstein K, Rascher M, Rupcic Z, Lowen E, Winter B, Koster RW, Stadler M. Corallocins A-C, nerve growth and brain-derived neurotrophic factor inducing metabolites from the mushroom Hericium coralloides. J Nat Prod. 2016;79:2264–9.View ArticlePubMedGoogle Scholar
  50. Han S, Jun J, Yang H, Oh T. Comparison of physiological activity of solvent extracts from Hericium erinaceus. Ind J Sci & Tech. 2015;8Google Scholar
  51. Schlafer S, Raarup MK, Meyer RL, Sutherland DS, Dige I, Nyengaard JR, Nyvad B. pH landscapes in a novel five-species model of early dental biofilm. PLoS One. 2011;6:e25299.View ArticlePubMedPubMed CentralGoogle Scholar
  52. Okada A, Igarashi M, Okajima T, Kinoshita N, Umekita M, Sawa R, Inoue K, Watanabe T, Doi A, Martin A, Quinn J, Nishimura Y, Utsumi R. Walkmycin B targets WalK (YycG), a histidine kinase essential for bacterial cell growth. J Antibiot (Tokyo). 2010;63:89–94.View ArticleGoogle Scholar
  53. Eguchi Y, Kubo N, Matsunaga H, Igarashi M, Utsumi R. Development of an antivirulence drug against Streptococcus mutans: repression of biofilm formation, acid tolerance, and competence by a histidine kinase inhibitor, walkmycin C. Antimicrob Agents Chemother. 2011;55:1475–84.View ArticlePubMedPubMed CentralGoogle Scholar
  54. Barbier J, Wegner J, Benson S, Gentzsch J, Pietschmann T, Kirschning A. Total synthesis of a noricumazole a library and evaluation of HCV inhibition. Chemistry. 2012;18:9083–90.View ArticlePubMedGoogle Scholar
  55. Beck S, Henss L, Weidner T, Herrmann J, Muller R, Chao YK, Grimm C, Weber C, Sliva K, Schnierle BS. Identification of entry inhibitors of Ebola virus pseudotyped vectors from a myxobacterial compound library. Antivir Res. 2016;132:85–91.View ArticlePubMedGoogle Scholar
  56. Rachid S, Scharfe M, Blocker H, Weissman KJ, Muller R. Unusual chemistry in the biosynthesis of the antibiotic chondrochlorens. Chem Biol. 2009;16:70–81.View ArticlePubMedGoogle Scholar
  57. Zaburannyi N, Bunk B, Maier J, Overmann J, Muller R. Genome analysis of the fruiting body-forming Myxobacterium Chondromyces crocatus reveals high potential for natural product biosynthesis. Appl Environ Microbiol. 2016;82:1945–57.View ArticlePubMedPubMed CentralGoogle Scholar
  58. Pistorius D, Li Y, Sandmann A, Muller R. Completing the puzzle of aurachin biosynthesis in Stigmatella aurantiaca sg a15. Mol BioSyst. 2011;7:3308–15.View ArticlePubMedGoogle Scholar
  59. Enomoto M, Kitagawa W, Yasutake Y, Shimizu H. Total synthesis of aurachins C, D, and L, and a structurally simplified analog of aurachin C. Biosci Biotechnol Biochem. 2014;78:1324–7.View ArticlePubMedGoogle Scholar
  60. Irschik H, Gerth K, Hofle G, Kohl W, Reichenbach H. The myxopyronins, new inhibitors of bacterial RNA synthesis from Myxococcus fulvus (Myxobacterales). J Antibiot (Tokyo). 1983;36:1651–8.View ArticleGoogle Scholar
  61. Doundoulakis T, Xiang AX, Lira R, Agrios KA, Webber SE, Sisson W, Aust RM, Shah AM, Showalter RE, Appleman JR, Simonsen KB. Myxopyronin B analogs as inhibitors of RNA polymerase, synthesis and biological evaluation. Bioorg Med Chem Lett. 2004;14:5667–72.View ArticlePubMedGoogle Scholar
  62. Moy TI, Daniel A, Hardy C, Jackson A, Rehrauer O, Hwang YS, Zou D, Nguyen K, Silverman JA, Li Q, Murphy C. Evaluating the activity of the RNA polymerase inhibitor myxopyronin B against Staphylococcus aureus. FEMS Microbiol Lett. 2011;319:176–9.View ArticlePubMedGoogle Scholar
  63. Julien B, Tian ZQ, Reid R, Reeves CD. Analysis of the ambruticin and jerangolid gene clusters of Sorangium cellulosum reveals unusual mechanisms of polyketide biosynthesis. Chem Biol. 2006;13:1277–86.View ArticlePubMedGoogle Scholar

Copyright

Advertisement